复发性上皮性卵巢癌女性的姑息性全身治疗：现有选择。
Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options.
机构信息
Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada ; Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
出版信息
Onco Targets Ther. 2013;6:107-18. doi: 10.2147/OTT.S30238. Epub 2013 Feb 26.
Abstract
OBJECTIVES
To review the available systemic treatments for women with recurrent ovarian cancer.
METHODS
A literature review was conducted for recurrent ovarian cancer articles in English, including randomized trials, Phase II trials, or reviews.
RESULTS
We discuss the efficacy and toxicity outcomes associated with systemic therapy for platinum-sensitive and platinum-resistant ovarian cancer. Clearly, platinum-based combination systemic therapy shows a prolonged progression-free interval compared with single-agent chemotherapy with a low toxicity profile. No clear superior management strategy exists for platinum-resistant/refractory disease. Novel targeted antiangiogenic agents (eg, bevacizumab), angiopoeitin inhibitors (eg, AMG 386), and poly ADP ribose polymerase inhibitors (eg, olaparib) are reviewed.
CONCLUSION
Although combination platinum-based chemotherapy has shown benefits for women with platinum-sensitive recurrent ovarian cancer, the optimal treatment strategy for those with platinum-resistant or platinum-refractory disease is not clear. Molecular and genetic targeted therapies may provide opportunities for those women with tumor profiles that show sensitivity for specific agents.
摘要
目的
综述女性复发性卵巢癌的现有全身治疗方法。
方法
对英文复发性卵巢癌相关文献进行了综述，包括随机试验、Ⅱ期试验或综述。
结果
我们讨论了与铂敏感和铂耐药卵巢癌全身治疗相关的疗效和毒性结果。显然，与低毒性单药化疗相比，铂类联合全身化疗显示出更长的无进展间期。对于铂耐药/难治性疾病，尚无明确的优势管理策略。新型靶向抗血管生成药物（如贝伐珠单抗）、血管生成素抑制剂（如 AMG 386）和多聚 ADP 核糖聚合酶抑制剂（如奥拉帕尼）也进行了综述。
结论
虽然含铂化疗方案对铂敏感复发性卵巢癌患者有益，但铂耐药或铂难治性疾病患者的最佳治疗策略尚不清楚。分子和基因靶向治疗可能为那些肿瘤特征显示对特定药物敏感的患者提供机会。
相似文献
1
Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options.复发性上皮性卵巢癌女性的姑息性全身治疗：现有选择。
Onco Targets Ther. 2013;6:107-18. doi: 10.2147/OTT.S30238. Epub 2013 Feb 26.
2
Optimal chemotherapy treatment for women with recurrent ovarian cancer.复发性卵巢癌女性的最佳化疗治疗。
Curr Oncol. 2007 Oct;14(5):195-208. doi: 10.3747/co.2007.148.
3
Treatment of recurrent ovarian cancer.复发性卵巢癌的治疗。
Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56. doi: 10.1093/annonc/mdx441.
4
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.尼拉帕利联合贝伐珠单抗对比尼拉帕利单药用于铂敏感复发性卵巢癌（NSGO-AVANOVA2/ENGOT-ov24）：一项随机、2 期、优效性试验。
Lancet Oncol. 2019 Oct;20(10):1409-1419. doi: 10.1016/S1470-2045(19)30515-7. Epub 2019 Aug 29.
5
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.奥拉帕利联合化疗治疗复发性铂类敏感卵巢癌：一项随机 2 期临床试验。
Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4.
6
An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.上皮性卵巢癌的当前及新出现疗法的最新进展：聚焦于聚（二磷酸腺苷 - 核糖）聚合酶抑制和抗血管生成。
J Oncol Pharm Pract. 2017 Sep;23(6):454-469. doi: 10.1177/1078155216657165. Epub 2016 Jun 29.
7
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.复发性卵巢癌的治疗选择：最新证据和临床潜力。
Ther Adv Med Oncol. 2014 Sep;6(5):229-39. doi: 10.1177/1758834014544121.
8
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.拓扑替康、聚乙二醇化脂质体盐酸多柔比星和紫杉醇用于晚期卵巢癌二线或后续治疗：一项系统评价和经济学评估
Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. doi: 10.3310/hta10090.
9
Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment.复发性卵巢癌二线铂类化疗后治疗选择：主动监测与维持治疗比较。
Cancer Treat Rev. 2020 Nov;90:102107. doi: 10.1016/j.ctrv.2020.102107. Epub 2020 Sep 21.
10
Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives.贝伐单抗治疗铂耐药卵巢癌的概况：当前观点
Int J Womens Health. 2016 Mar 15;8:59-75. doi: 10.2147/IJWH.S78101. eCollection 2016.
引用本文的文献
1
Targeting autophagy in platinum-sensitive relapsed ovarian cancer: randomized phase II trial of hydroxychloroquine with chemotherapy with biomarker correlation.针对铂敏感复发性卵巢癌的自噬：羟氯喹联合化疗的随机II期试验及生物标志物相关性研究
Discov Oncol. 2025 Feb 19;16(1):203. doi: 10.1007/s12672-025-01904-w.
2
FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor Microenvironment.FF-10850，一种新型脂质体拓扑替康，通过肿瘤微环境中巨噬细胞和氨介导的有效载荷释放实现优异的抗肿瘤活性。
Mol Cancer Ther. 2023 Dec 1;22(12):1454-1464. doi: 10.1158/1535-7163.MCT-23-0099.
3
Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tunning as Multi-Target Therapeutics against Ovarian Cancers.调控 AMPK 激活和联合 VEGF/PD-1 阻断与脂质代谢调谐作为多靶点治疗卵巢癌。
Int J Mol Sci. 2022 Jun 20;23(12):6857. doi: 10.3390/ijms23126857.
4
Surgery in platinum-resistant recurrent epithelial ovarian carcinoma.铂耐药复发性上皮性卵巢癌的手术治疗
World J Clin Cases. 2022 Apr 26;10(12):3739-3753. doi: 10.12998/wjcc.v10.i12.3739.
5
A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.阿帕替尼治疗铂耐药或铂抵抗复发性上皮性卵巢癌的回顾性观察性研究。
Drug Des Devel Ther. 2021 Jan 27;15:339-347. doi: 10.2147/DDDT.S286529. eCollection 2021.
6
Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy.复发性高级别浆液性卵巢癌采用细胞毒化疗的真实世界直接医疗成本。
J Comp Eff Res. 2020 Jun;9(8):537-551. doi: 10.2217/cer-2020-0032. Epub 2020 Mar 30.
7
Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review.复发性上皮性卵巢癌的维持治疗：当前疗法与未来展望——综述。
J Ovarian Res. 2019 Nov 4;12(1):103. doi: 10.1186/s13048-019-0579-0.
8
9
Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer.聚腺苷二磷酸核糖聚合酶抑制剂在晚期卵巢癌中的作用
Cureus. 2018 May 24;10(5):e2685. doi: 10.7759/cureus.2685.
10
Advances in ovarian cancer therapy.卵巢癌治疗进展。
Cancer Chemother Pharmacol. 2018 Jan;81(1):17-38. doi: 10.1007/s00280-017-3501-8. Epub 2017 Dec 16.
本文引用的文献
1
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.先例：一项比较 vintafolide（EC145）联合聚乙二醇脂质体多柔比星（PLD）与 PLD 单药治疗铂耐药卵巢癌患者的随机 II 期试验。
J Clin Oncol. 2013 Dec 10;31(35):4400-6. doi: 10.1200/JCO.2013.49.7685. Epub 2013 Oct 14.
2
Clinical trials and future potential of targeted therapy for ovarian cancer.卵巢癌靶向治疗的临床试验和未来潜力。
Int J Clin Oncol. 2012 Oct;17(5):430-40. doi: 10.1007/s10147-012-0459-8. Epub 2012 Aug 28.
3
A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.马来酸舒尼替尼治疗复发性和难治性卵巢、输卵管及腹膜癌的 II 期临床试验。
Gynecol Oncol. 2013 Feb;128(2):215-20. doi: 10.1016/j.ygyno.2012.07.126. Epub 2012 Aug 9.
4
Role of farletuzumab in epithelial ovarian carcinoma.法乐妥珠单抗在卵巢上皮性癌中的作用。
Curr Pharm Des. 2012;18(25):3812-5. doi: 10.2174/138161212802002698.
5
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.OCEANS：一项在铂敏感复发性上皮性卵巢癌、原发性腹膜癌或输卵管癌患者中进行的化疗联合或不联合贝伐珠单抗的随机、双盲、安慰剂对照 III 期试验。
J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23.
6
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy.一项针对铂类耐药性卵巢癌的 II 期临床试验（AGO 2.11）：一项随机多中心试验，采用舒尼替尼（SU11248）评估一种多靶点受体酪氨酸激酶抑制剂单药治疗的剂量、方案、耐受性、毒性和疗效。
Ann Oncol. 2012 Sep;23(9):2265-2271. doi: 10.1093/annonc/mds003. Epub 2012 Feb 29.
7
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.BRCA1 或 BRCA2 突变复发性卵巢癌患者中聚（ADP-核糖）聚合酶抑制剂奥拉帕利与多柔比星脂质体比较疗效和安全性的 II 期、开放标签、随机、多中心研究。
J Clin Oncol. 2012 Feb 1;30(4):372-9. doi: 10.1200/JCO.2011.36.9215. Epub 2011 Dec 27.
8
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.静脉注射阿柏西普治疗晚期卵巢癌复发性有症状恶性腹水患者：一项 2 期、随机、双盲、安慰剂对照研究。
Lancet Oncol. 2012 Feb;13(2):154-62. doi: 10.1016/S1470-2045(11)70338-2. Epub 2011 Dec 20.
9
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.一项评价 AMG 386 联合每周紫杉醇治疗复发性卵巢癌患者的随机、双盲、安慰剂对照 II 期研究。
J Clin Oncol. 2012 Feb 1;30(4):362-71. doi: 10.1200/JCO.2010.34.3178. Epub 2011 Dec 19.
10
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.奥拉帕利治疗复发性高级别浆液性或低分化卵巢癌或三阴性乳腺癌患者的疗效：一项多中心、开放标签、非随机的 2 期临床试验。
Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19.
Zotero 插件